

News Release

HYDERABAD, INDIA (9 Aug 2021) -- SUVEN Life Sciences Limited ("Suven") today announced unaudited financial results for the quarter ended 30 June 2021. The unaudited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 9 Aug 2021 at Hyderabad.

CONSOLIDATED STATEMENT OF OPERATIONS

INR Million, except EPS

	Quarter ended			Year ended
	30-Jun-21	31-Mar-21	30-Jun-20	31-Mar-21
<i>Revenue</i>	65.61	28.80	39.58	212.32
R&D and Operational expenses	445.83	231.39	156.54	935.44
Depreciation and Amortisation	10.34	10.66	10.65	43.46
Finance cost	1.53	2.42	1.96	8.15
<i>Total expenses</i>	457.70	244.47	169.14	987.06
Tax	-	0.46	(24.67)	(53.23)
<i>Profit/(Loss) After Tax for the period/year</i>	(392.09)	(216.12)	(104.89)	(721.51)
Other comprehensive income	(1.18)	(0.85)	(0.74)	(3.07)
<i>Total comprehensive income</i>	(393.26)	(216.98)	(105.63)	(724.58)
Paid up equity capital	127.28	127.28	127.28	127.28
<i>Earnings per share of Rs.1 each (EPS)</i>	(3.08)	(1.70)	(0.82)	(5.67)

- (a) Suven, a Biopharmaceutical company, engaged in Drug Discovery and Development of New Chemical Entities (NCEs) in Central Nervous System (CNS) disorders targeting unmet medical needs, globally.
- (b) The statement of operations includes financial of Suven Neurosciences, Inc., a Delaware Company, wholly owned subsidiary (WOS) of Suven, involved in clinical development programs of the Company.
- (c) Clinical development pipeline:
- SUVN-502 (Masupirdine) – Completed phase 2 study on Alzheimer’s in USA and to be initiated phase 2/3 study on Agitation and Aggression in Alzheimer’s type dementias in North America and Europe; expected completion by the year end 2024
 - SUVN-G3031 (Samelisant) – Ongoing phase 2 study on Narcolepsy in North America; expected completion by the year end 2022
 - SUVN-D4010 (Usmarapride) – Completed phase 1 study
 - SUVN-911 (Ropanicant) – Completed phase 1 study
- (d) Since last reporting period, the Company has been granted 22 patents for its innovative drug discovery covering ARIPO, Australia, China, Europe, Hong Kong, Israel, Macao, Mexico, New Zealand, Sri Lanka, and USA.

[For more information on Suven please visit our Web site at http://www.suven.com](http://www.suven.com)

Risk Statement:

Except for historical information, all the statements, expectations, and assumptions, including expectations and assumptions, contained in this news release may be forward-looking that involve several risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including research and clinical development outcome, outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances, and continued success in growth of revenue that may make our products/services offerings less competitive.